Frontiers in Pharmacology · 2022 · 22 citations · 50 references
PharmacyPharmacokineticsPharmacologyDrug ClearancePharmacokinetic ModelingPopulation PharmacokineticsDose OptimizationPharmacodynamics In Critical IllnessPharmacokinetics In Critical IllnessPharmacokinetics Of AntimicrobialsPopulation Pharmacokinetic ModelingPopulation Pharmacokinetic-pharmacodynamic ModelingCreatinine Clearance ModelingCritical Care Drug DosingCritically Ill Patient DosingCritically Ill Patient Drug ClearanceDrug Trough ConcentrationLinezolid DosingLinezolid TherapyRenal Function Covariates
Background: Linezolid is associated with myelosuppression, which may cause failure in optimally treating bacterial infections. The study aimed to define the pharmacokinetic/toxicodynamic (PK/TD) threshold for critically ill patients and to identify a dosing strategy for critically ill patients with renal insufficiency. Methods: The population pharmacokinetic (PK) model was developed using the NONMEM program. Logistic regression modeling was conducted to determine the toxicodynamic (TD) threshold of linezolid-induced myelosuppression. The dosing regimen was optimized based on the Monte Carlo simulation of the final model. Results: PK analysis included 127 linezolid concentrations from 83 critically ill patients at a range of 0.25–21.61 mg/L. Creatinine clearance (CrCL) was identified as the only covariate of linezolid clearance that significantly explained interindividual variability. Thirty-four (40.97%) of the 83 patients developed linezolid-associated myelosuppression. Logistic regression analysis showed that the trough concentration (C min ) was a significant predictor of myelosuppression in critically patients, and the threshold for C min in predicting myelosuppression with 50% probability was 7.8 mg/L. The Kaplan–Meier plot revealed that the overall median time from the initiation of therapy to the development of myelosuppression was 12 days. Monte Carlo simulation indicated an empirical dose reduction to 600 mg every 24 h was optimal to balance the safety and efficacy in critically ill patients with CrCL of 30–60 ml/min, 450 mg every 24 h was the alternative for patients with CrCL <30 ml/min, and 600 mg every 12 h was recommended for patients with CrCL ≥60 ml/min. Conclusion: Renal function plays a significant role in linezolid PKs for critically ill patients. A dose of 600 mg every 24 h was recommended for patients with CrCL <60 ml/min to minimize linezolid-induced myelosuppression.
50
Anand Kumar, Daniel Roberts, Kenneth E. Wood et al. · Critical Care Medicine · 2006 · 6.1K citations
Veterinary Medicine, Infectious Diseases, Antimicrobial Pharmacotherapy +13
Inadequate Antimicrobial Treatment of Infections
Marin H. Kollef, Glenda Sherman, Suzanne M. Ward et al. · CHEST Journal · 1999 · 1.8K citations
Hematologic Effects of Linezolid: Summary of Clinical Experience
Stanton L. Gerson, Sheldon L. Kaplan, Jon Bruss et al. · Antimicrobial Agents and Chemotherapy · 2002 · 443 citations · Full text
Medicine, Hematology, Pharmacology +14